The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Emerging therapies to address the unmet need for triple-class refractory multiple myeloma
Maria Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses emerging therapies for triple-class refractory patients with multiple myeloma (MM). These include BCMA and GPRC5D-targeted agents like bispecifics, CAR-Ts, and belantamab mafodotin. For patients refractory to these treatments, ongoing research is focused on cereblon E3 ligase modulators (CELMoDs) and melflufen. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
